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Kidney TransplantationRegulatory T-cell Number in Peripheral Blood at
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Juan C. Ruiz, MD, PhD,2 Gema Fernández-Fresnedo, MD, PhD,2 Laura Riesco, BSc,1 Jairo Bada, MD,2
Lara Belmar, MD,2 and Marcos Lopez-Hoyos, MD, PhD1Background. Regulatory T (Treg) cells play a role in limiting kidney transplant rejection and can potentially promote long-term
transplant tolerance. There are no large prospective studies demonstrating the utility of peripheral blood Treg cells as biomarkers
for long-term graft outcome in kidney transplantation. The aim of our study was to analyze the influence of the absolute number of
peripheral blood Treg cells after transplantation on long-term death-censored graft survival.Methods.Wemonitored the absolute
numbers of Treg cells by flow cytometry in nonfrozen samples of peripheral blood in 133 kidney transplant recipients, who were
prospectively followed up to 2 years after transplantation. Death-censored graft survival was determined retrospectively in January
2017. Results. The mean time of clinical follow-up was 7.4 ± 2.9 years and 24.1% patients suffered death-censored graft loss
(DCGL). Patients with high Treg cells 1 year after transplantation and above themedian value (14.57 cells/mm3), showed better death-
censored graft survival (5-year survival, 92.5% vs 81.4%, Log-rank P = .030). One-year Treg cells showed a receiver operating
characteristic - area under curve of 63.1% (95% confidence interval, 52.9–73.2%, P = 0.026) for predicting DCGL. After
multivariate Cox regression analysis, an increased number of peripheral blood Treg cells was a protective factor for DCGL
(hazard ratio, 0.961, 95% confidence interval, 0.924–0.998, P = 0.041), irrespectively of 1-year proteinuria and renal function.
Conclusions. Peripheral blood absolute numbers of Treg cells 1 year after kidney transplantation predict a better long-term
graft outcome and may be used as prognostic biomarkers.
(Transplantation Direct 2019;5: e426; doi: 10.1097/TXD.0000000000000871. Published online 8 February, 2019.)Aprogressive reduction in acute rejection rates has ledto an improvement of kidney graft survival (KGS)
throughout the first year, but long-term graft attrition rates
remain stable beyond this point.1 Despite the good results
in KGS during the first year, this poor long-term outcome
should be improved.2 Moreover, the use of immunosup-
pressive drugs provokes an increase in infection and can-
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Transplantation DIRECT ■ 2019individualization strategies in the immunosuppressant
treatment is the goal in order to avoid these adverse effects
on the kidney transplant recipient (KTR).3 The reasons
for the scarce improvement in KGS are at present under
research and the focus is on noninvasive biomarkers as
a tool to modulate the immunosuppressant dosing and
to predict the survival of the transplanted graft.4
The results of in vivo and in vitro studies have suggested an
important role of regulatory T (Treg) cells in the field of or-
gan transplantation due to their capacity to suppress effectorSupplemental digital content (SDC) is available for this article. Direct URL citations
appear in the printed text, and links to the digital files are provided in the HTML
text of this article on the journal’s Web site (www.transplantationdirect.com).
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2 Transplantation DIRECT ■ 2019 www.transplantationdirect.comimmune responses.4,5 Treg cells have been studied in vivo in
biopsies of KTRs with promising results, showing a picture
of local immune status. However, this invasive procedure
could lead to some risks for the graft and is limited by sam-
pling error and inter-observer variability.6 Noninvasive stud-
ies analyzing the Treg cell-associated gene expression in urine
might offer a safer means of improving the prediction of the
outcome in renal transplants, although it has not been trans-
lated into clinical routine.7 An intermediate option could be to
measure Treg cell numbers in peripheral blood, being both
minimally invasive and ready to perform. Several studies
have related a lower Treg cell level and Treg cell-related
mRNA in peripheral blood samples with chronic graft injury
in cross-sectional studies,8-15 but the association of Treg cells
with a better kidney transplant outcome has not been consis-
tently found in all the studies.16,17
Due to their recent description, there are no long-term pro-
spective studies in KTRs, which monitor peripheral blood
Treg cell levels and their association with graft outcome. In
2012, we reported the relationship between a high peripheral
blood Treg cell level at 12 months posttransplantation and a
long-term better graft survival with a mean follow-up of
62 months in 90 KTRs.18 In the current study, we show the
extension results of the complete cohort consisting of 133
kidney transplants where the Treg cells were prospectively
measured in peripheral blood at 6 and 12 months between
2005 and 2011, andwhere the patients were followed up until
January 2017. Importantly, the levels of Treg cells in this study
were measured at the same laboratory and in fresh samples.
This is of special importance because severalworks have pointed
at a loss of Treg cell phenotype markers after freezing.19
METHODS
Patients
A total of 133 consecutive KTR operated in our hospital
between 2005 and 2011 were included in the study. The studyTABLE 1.
Clinical, demographical, and immunological variables of KTRs
Clinical, demographic, and immunological variables DCG
Donor age: mean ± SD, y 53.3
Recipient age: mean ± SD, y 54.3
Recipient sex (n), F/M 7
HLA-A/-B/-DR matches, mean 0.56/0
Sensitized, n (%) 8
Peak panel reactive of antibodies, mean ± SD 4.91
Current panel reactive of antibodies, mean ± SD 3.21
Delayed graft function, n (%) 7










AZA, azathioprine; CsA, cyclosporine; F, female; IS, immunosuppression; M, male; MMF, mycophenolate m
thymoglobulin; Tx, transplant.was approved by the ethics committee of the hospital; all the
patients were informed about the study and gave their written
consent. The main demographic, clinical, and immunologic
parameters are depicted in Table 1. The patients were moni-
tored before transplant and at 6, 12, and 24months postkidney
transplantation. The diagnosis of acute rejection was biopsy-
proven. Death-censored graft loss (DCGL) was defined as a
return to dialysis therapy or re-transplantation. The causes
of DCGL are summarized in Table S1, http://links.lww.
com/TXD/A179. The immunosuppression was maintained
based on trough levels from 4 months posttransplant.
Flow Cytometry
We identified Treg cells as CD4+CD25+CD127-/lowFoxp3+
cells. More than 95% of CD4+CD25highFoxp3+ were
CD127-/low. Peripheral blood effector and regulatory sub-
populations were quantified by flow cytometry, as previously
described.20,21 All samples were processed from fresh blood
within the first 4 hours after their extraction, and acquired in
a FACScalibur (BD Biosciences, San Jose, CA) before 2008,
using FACSCanto II (BD Biosciences) thereafter. Daily BD
FACS Comp and weekly CST QC (BD Biosciences) were
used on FACScalibur and FACSCanto II, respectively, to
monitor cytometers performance. The acquisition protocols
with both cytometers were validated (Figures S1, http://
links.lww.com/TXD/A180 and S2, http://links.lww.com/
TXD/A181), and the software for flow cytometry analysis
was FACS Diva (BD Biosciences).
Statistics
The Treg cell levels were nonparametrically distributed as
determined by the Kolmogorov-Smirnov fit test. A compari-
son of Treg cells at different timepoints was assessed by the
Wilcoxon paired rank test. Correlations of Treg cell levels
at different times were assessed by the Spearman correlation.
Graft survival was tested by the Kaplan-Meier survival test.
Univariate and multivariate Cox regression analyses andL (32) No DCGL (101) P
± 16.5 51.4 ± 15.6 .54
± 13.6 51.4 ± 11.9 .25
/25 27/74 .58
.50/0.70 0.61/0.43/0.65 .66/.56/.65
(25) 20 (19.8) .58
± 14.07 3.37 ± 10.01 .50
± 9.15 0.51 ± 2.57 .11
(5.2) 20 (15) .80








ofetil; mTORi, mammalian target of rapamycin inhibitors;SD, standard deviation; Tac, tacrolimus; TG,
© 2019 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. Segundo et al 3receiver operating characteristic curve analysis were performed
to establish the robust nature of associations. Statistical anal-
ysis was performed by using SPSS version 15.0 (SPSS Inc.,
Chicago, IL).FIGURE 2. Association of early posttransplant Regulatory T (Treg)
cell levels and risk of death-censored graft loss (DCGL). The Treg cell
levels before transplant, at 6 and 12 months postkidney transplanta-
tion were assessed for risk of DCGL by univariate Cox regression
analysis. Treg cell levels were analyzed as a continuous variable.RESULTS
All patients had aminimum follow-up of 5 years, themean
follow-up being 7.4 ± 2.9 years, and the graft lost rate in our
cohort was 30.8%. Peripheral blood Treg cell levels de-
creased significantly at 6 months (P = .0005) with partial
recovery from basal levels at 1 year posttransplantation: me-
dian and interquartile range pretransplantation, at 6 months
and 1 year posttransplantation were 16.95 [8.54–29.38]
cells/mm3, 11.12 [5.41–20.69] cells/mm3, and 13.07 [6.62–
23.28] cells/mm3, respectively. Peripheral blood Treg cell levels
at 12 and 24 months remained unchanged from levels at
6 months after kidney transplantation (Figure 1).
We assessed the impact of Treg cell levels before transplan-
tation, then at 6 months and 12 months posttransplantation
on the risk of DCGL, and analyzed it as a continuous vari-
able. A protective association of Treg cell levels at 12 months
postkidney transplant for DCGL was found (Figure 2; hazard
ratio [HR], 0.957; 95% confidence interval [CI], 0.922-0.993;
P = .019), but neither pretransplantation nor 6 months Treg
cell numbers showed any relationship to long-term graft
survival. Receiver operating characteristic-area under curve
of Treg cells at 12 months for predicting DCGL was 63.1%
(95% CI, 52.9–73.2%; P = .026). The best cutoff value of
Treg cells at 12 months posttransplantation to discriminate
kidney transplant patients at risk for DCGL was 14.57 Treg
cells/mm3, showing a sensitivity and specificity of 51.5% and
75%, respectively, for DCGL (Figure 3).
Therefore, we did not find an optimal value of Treg cells
that would allow us to stratify patients properly, even moreFIGURE 1. Regulatory T (Treg) cell levels in kidney transplant recip-
ients (KTRs). (A) The comparison of the number of Treg cell/mm3 in
peripheral blood of KTRs is depicted and median and interquartile
range are shown at different time points (pretransplant, open circles;
6 months posttransplant, open squares; 12 months posttransplant,
open triangles; and 24 months posttransplant, open diamonds). Treg
cell changes were assessed by the Wilcoxon paired rank test and
levels of significance were indicated as **P < .01, ***P < .001, and
****P < .0001.so because the Treg cell levels were nonnormally distributed.
We decided to stratify the patients based on 12-month Treg
cell level tertiles.ThosepatientswithTreg cell levels at12months
which were>19.51 cells/mm3 were considered “High Treg cell
group,”whereas those with Treg cell<7.63 cells/mm3 were in-
cluded in “Low Treg cell group.” Patients in the high Treg cell
group had better death-censored graft survival, although this
did not reach statistical significance (Log-rank P = .146)
(Figure 4).
Toassess the independent role ofTreg cell levels at 12months
postkidney transplantation in DCGL, a multivariate Cox re-
gression model was performed with variables classically in-
volved in DCGL. Among them, we included age at transplant,
cold ischemia time, antibody production during the first year,
donor age, delayed graft function, biopsy-proven acute rejec-
tion with first year, serum creatinine at first year, proteinuria
at first year, and absolute numbers of Treg cells at first year
(Table 2). A high number of Treg cells in peripheral blood
at 12 months after transplantation was a protective factor
for DCGL, irrespectively of proteinuria or creatinine at
12 months (HR, 0.961; 95% CI, 0.924–0.998; P = .041).
However, such an association did not reach statistical signif-
icance when considering the percentages of Treg cells
(Table S2, http://links.lww.com/TXD/A182).DISCUSSION
The function of Treg cells controlling alloimmune response
both in vivo and in vitro has led to propose their role as po-
tential biomarkers of graft outcome.4,22 Some studies have
focused on the presence of Treg cells in kidney biopsies,7,23
but the identification of the Foxp3+ regulatory cells within
the allograft cannot help to differentiate between cytotoxic
or tolerogenic infiltrates24 and the risk of side effects after biopsy
discourages its use in monitoring the renal graft. On the con-
trary, the quantification of Treg cells in peripheral blood is
readily accessible for most laboratories with limited drawbacks
by using adequate Treg cell markers.4
Hence, different authors have reported that patients with
chronic allograft nephropathy showed a lower number of
peripheral blood Treg cells than those with stable graft
FIGURE 3. (A) Receiver operational curve analysis of regulatory T (Treg) cell levels at 12 months posttransplant and death-censored graft loss
(DCGL). The area under curve (AUC) is 63.1%. A cutoff of 14.57 Treg cells/mm3 in peripheral blood discriminates between DCGL and non-DCGL
after kidney transplantation with a sensitivity and a specificity of 51.5% and 75%, respectively. (B) Tertile distribution of Treg cell levels at 12-month
postkidney transplantation. Red circles in first tertile and blue circles in third tertile are depicted. White circles represent the second tertile.
4 Transplantation DIRECT ■ 2019 www.transplantationdirect.comfunction.8,11-15 Conversely, a higher number of peripheral
blood Treg cells has been reported as amarker of operational
tolerance in kidney and liver transplant studies, although this
finding has not been confirmed in all studies.11,14,25Moreover,
Lin et al26 have reported a positive linear relationship between
the percentage of Treg cells in peripheral blood lymphocytes
and the estimated glomerular filtration rate in kidney trans-
plant patients. All these studies were cross-sectional, per-
formed at different points after transplantation, and they
included a low number of patients. The main finding of our
current study is that for the first time we have reported an in-
dependent relationship between 1 year after transplantation
peripheral blood Treg cell number and long-term KGS. In a
preliminary study, we reported the relationship between a high
peripheral blood Treg cell level at 12 months posttransplanta-
tion and a long-term better graft survival with a shorter
follow-up in 90 KTRs by only univariate analysis.18 In theFIGURE 4. Regulatory T (Treg) cell level stratification and death-censore
based on tertiles of Treg cell levels at 12 months postkidney transplantat
shown in red; below third tertile, low Treg cell levels (7.63 Treg cells/mm
shown in black. No statistically significant differences were found amon
the number of patients at risk in each group at the given timepoints.current study, we presented the data with a longer follow-
up, including up to 133 patients and carrying out a multivar-
iate study.We did not find an optimal cutoff value of Treg cells
that could help to differentiate those KTRs who were going to
have a worse graft outcome, but we can conclude that patients
with a higher number of circulating Treg cells at 12monthwill
have a better long-term graft outcome. Besides, this relation-
ship was independent of other variables, which were strongly
related with graft outcome, such as renal function and protein-
uria. Although we cannot conclude a causal link between the
number of Treg cells and a good graft outcome with our de-
sign, this finding meets some criteria for the establishment of
a cause and effect relationship, such as coherence with
known facts, biological plausibility and temporal and dose-
response relationships. Despite all this, we have not specifi-
cally addressed the relationship between Treg cell number
and the causes of graft loss due to their heterogeneousd graft survival. The kidney transplant recipients (KTRs) were stratified
ion. Above first tertile, high Treg cell levels (19.51 Treg cells/mm3) are
3) are shown in blue; and second tertile medium Treg cell levels are
g the 3 tertiles by the Kaplan-Meier analysis. The lower table shows
TABLE 2.
Univariate and multivariate assessments of DCGL after kidney transplantation
Parameters Univariate HR (95% CI) Multivariate HR (95% CI)
12-month proteinuria <0.001 1.001 (1.00-1.001) <0.001 1.001 (1.00-1.001)
12-month serum creatinine <0.001 3.49 (2.11-5.774) 0.004 2.37 (1.32-4.25)
12-month Treg cell numbers 0.019 0.957 (0.922-0.993) 0.040 0.96 (0.924-0.998)
Recipient age 0.143 1.023 (0.992-1.055) 0.39 1.014 (0.982-1.048)
12-month AR 0.231 1.603 (0.741-3.469)
Donor age 0.279 1.013 (0.99-1.036)
DGF 0.830 1.096 (0.474-2.536)
Cold ischemia 0.841 1.006 (0.949-1.067)
AR, acute rejection; CI, confidence interval; DCGL, death-censored graft loss; DGF, delayed graft function; HR, hazard ratio; Treg, regulatory T.
© 2019 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. Segundo et al 5etiology. As reported in Table S1, http://links.lww.com/TXD/
A179, of 23 patients with a biopsy-proven cause of graft loss,
an alloimmune etiology was only diagnosed in 11 patients
who suffered antibody-mediated rejection, whereas glomerulo-
nephritis recurrence was established in 4 patients, with non-
specific interstitial fibrosis and tubular atrophy was diagnosed
in 5 patients. Of note, this distribution of causes of allograft
loss is similar to that previously reported.27
Importantly, our studywas performedwith fresh peripheral
blood samples. One of the reasons for the differences among
studies addressing the quantification of Treg cells in peripheral
blood has to dowith cryopreservation. Several studies showed
that freezing induces a loss of Treg cell phenotype, decreasing
the number of cells with such a phenotype.19 Nonetheless,
those cells with Treg cell phenotype maintained their suppres-
sive function after thawing.28 The importance of a standardized
protocol is crucial to having reproducible results in monitoring
Treg cells, as well as the use of fresh but not cryopreserved
samples.21
Our study also confirms previous suggestions about the
optimal moment to determine peripheral blood Treg cell
measurement as a biomarker to estimate long-term graft out-
come.4 This issue is important because peripheral blood Treg
cell numbers are not stable, and they change frompretransplant
values throughout the evolution of the transplant. Our group
and other authors described a reduction of Treg cell levels at
6 months postkidney transplantation from pretransplant
values,29,30 and this finding was also confirmed in multicen-
ter studies.21 After this reduction, the absolute count of Treg
cells at 12 months of kidney transplantation recover the
pretransplant levels.29 In the current study, Figure 2 shows
Treg cell numbers relatedwith the risk ofDCGL at 12months,
but not at pretransplant or at 6 months. Hence, their measure-
ment at this point could be useful as a potential biomarker of
further long-term kidney graft outcome. The use of circulating
Treg cell number at 24 months after transplantation did not
add any advantages in the present study. Besides, we consider
it important enough not to measure frequencies but absolute
numbers of Treg cells, because the statistical significance is lost
when considering the Treg cell frequencies in peripheral blood
(Table S2, http://links.lww.com/TXD/A182). On the other
hand, it should be taken into account that the patients suf-
fering from acute rejection would have received higher im-
munosuppression, which could interfere with Treg cell
numbers. In the univariate analysis excluding those pa-
tients with acute rejection at 1 year of transplantation,
the Treg cell levels were not significantly correlated withDCGL, but they did show a tendency (Table S3, http://links.
lww.com/TXD/A183). The use of immunosuppression may
induce a decrease in the absolute number of lymphocytes
with reflection in the numbers of T-cell subsets. However, it
cannot have consequences in the frequencies of those subsets,
as demonstrated by other authors.31,32
Obviously, the percentages and number of Treg cells
may be affected by immunosuppressive drugs. It is known
that calcineurin inhibitors have a deleterious effect on Treg
cells, whereas mammalian target of rapamycin (mTOR) in-
hibitors do not20,33 and that there is an inverse correlation
between the circulating Treg cells and tacrolimus blood
levels.29 It is possible that our data are limited, because
21 of the patients in our cohort experienced mTOR inhibi-
tion therapy at some moment after transplantation and this
could bias the results. Indeed, when only the patients in cal-
cineurin inhibitor therapy were selected, but never those with
mTOR inhibitors, the statistical significance of the influence
of Treg cells at 1 year after transplantation was missed, al-
though there was a trend (Table S4, http://links.lww.com/
TXD/A184). Regarding induction therapy, thymoglobulin
preserves circulating Treg cells,34 whereas anti-CD25 mono-
clonal antibodies cause a transient loss of peripheral blood
Treg cells35 with a phenotypic shift of Treg cells from the
CD25(+) to the CD25(−) compartment that does not seem to
be associated with functional consequences.36 Due to the
sample size, we did not find any relationship between the
type of induction therapy, the type of maintenance immuno-
suppressive drugs or the immunosuppressive blood levels and
the number of peripheral blood Treg cells (Tables S4–S6,
http://links.lww.com/TXD/A184, http://links.lww.com/
TXD/A185, http://links.lww.com/TXD/A186). Nonetheless,
we could be tempted to conclude that, to have a better
long-term graft outcome, we should select immunosuppres-
sive drugs that provide a higher number of Treg cells at
12 months posttransplantation, such as thymoglobulin in-
duction or mTOR inhibitors. Indeed, those patients who re-
ceived induction therapy almost doubled the number of
Treg cells at 12 month posttransplantation, and a high num-
ber of circulating Treg cells 12-month posttransplantation
showed a trend to protect from DCGL in multivariate analy-
sis, although it did not reach statistical significance (Table S5).
This conclusion cannot bemadewithout carrying out prospec-
tive randomized studies in humans, relating immunosuppres-
sive treatment, the number of regulatory cells at 12 months
and the long-term posttransplant evolution, similar to that in
animal models.37
6 Transplantation DIRECT ■ 2019 www.transplantationdirect.comTo conclude, we demonstrated that KTRs who have higher
levels of peripheral blood Treg cells at 12 months would have
a better long-term graft survival and this association was inde-
pendent of other 1-year variables, such as proteinuria and renal
function. Immunosuppressive treatments or interventions which
are able to maintain high Treg cell levels in peripheral blood
at 12 months postkidney transplantation could potentially
protect from long-term DCGL. One limitation of the present
study is that it was conducted in 1 center, whereas multicenter
studies should be addressed to better define cutoff values prior
to using Treg cell levels at 12months as a biomarker ofDCGL.
However, it has the advantage of being addressed in the clin-
ical routine with a well-established flow cytometry protocol
on fresh samples.
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